TMC-125 Tibotec.
TMC-125, a non-nucleoside reverse transcriptase inhibitor, is being developed by Tibotec for the potential treatment of HIV infection. Phase IIa trials in treatment-naive and treatment-experienced HIV-1-infected individuals had been completed by February 2002. A long-term, phase IIb, dose-finding study in treatment-experienced patients started enroling patients in a number of European countries during 2002, and Canada during 2003.
Haslinger
Bernhard A
BA
University Düsseldorf, Department of Neurology, Postfach 10 10 07, D-40001 Düsseldorf, Germany.
Arendt
Gabriele
G
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D009570:Nitriles; D011724:Pyridazines / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D013678:Technology, Pharmaceutical / Q000379:methods
D015507:Drugs, Investigational; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine